Related Experiment Videos
Properties of a "phase transition" induced by antiangiogenetic therapeutical protocols
1INFM, Dipartimento di Fisica, Politecnico di Torino, Torino, Italy.
Abstract:
Inhibiting angiogenesis has been found to be an interesting therapeutical strategy against cancer. In fact, the success of tumor growth is subordinated to the corresponding increase of the vascular system feeding the neoplasm. However, optimization and design of proper antiangiogenetic therapeutical strategies is still an open problem. We apply a recently developed angiogenesis model to study how variations in the relevant parameters, e.g., induced by chemicals, may cause a "phase transition" to a region in the parameter space in which angiogenesis is not succesful. To demonstrate the reliability of our approach and its usefulness, we will study some specific drugs and use our model to investigate the influence of the main variables involved in a clinical treatment: the administration time, the duration of the drug effect, and the drug dose.
Insights
This study uses a novel angiogenesis model to explore how drug treatments can inhibit tumor growth. By adjusting parameters like drug dose and administration time, researchers aim to find optimal anti-angiogenesis strategies for cancer therapy.
Area of Science:
- Oncology
- Biophysics
- Mathematical Biology
Background:
- Tumor growth relies on angiogenesis, the formation of new blood vessels.
- Developing effective anti-angiogenesis cancer therapies remains a significant challenge.
- Existing therapeutic strategies require optimization for maximum efficacy.
Purpose of the Study:
- To apply a new mathematical model of angiogenesis to identify conditions that inhibit tumor vascularization.
- To investigate how variations in drug-induced parameters can trigger a "phase transition" away from successful angiogenesis.
- To analyze the impact of key clinical treatment variables on anti-angiogenesis efficacy.
Main Methods:
- Utilizing a recently developed computational model of angiogenesis.
- Simulating the effects of parameter variations, such as those induced by chemical agents.
- Examining specific drugs to validate the model's predictions.
- Analyzing the influence of administration time, drug effect duration, and dosage.
Main Results:
- The model demonstrates that specific parameter alterations can lead to a state where angiogenesis is unsuccessful.
- Simulations show a "phase transition" in the parameter space, indicating a switch to inhibited vascularization.
- The study provides insights into how drug properties and administration schedules affect anti-angiogenic outcomes.
Conclusions:
- The developed angiogenesis model offers a reliable framework for optimizing anti-cancer drug strategies.
- Understanding parameter variations is crucial for designing effective treatments that target tumor angiogenesis.
- This approach can guide the clinical application of anti-angiogenesis drugs by informing dose and timing decisions.